Trials / Completed
CompletedNCT00000226
Alternate-Day Buprenorphine Administration. Phase VII - 8
Alternate-Day Buprenorphine Administration. Phase VII
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 21 Years – 48 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buprenorphine |
Timeline
- Start date
- 1994-11-01
- First posted
- 1999-09-21
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00000226. Inclusion in this directory is not an endorsement.